Nektar Therapeutics

Fineline Info & Tech (Flcube.com) provides you with comprehensive information about Nektar Therapeutics, including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare. More information about Nektar Therapeutics please access flcube.com

Company Drug

Mabwell to Present Phase II Data for Nectin‑4 ADC 9MW2821 at ESMO 2026 – 30.0% ORR in Post‑TOP1i‑ADC Triple‑Negative Breast Cancer, Headlining Four Phase III Programs

Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062; HKG: 2493) announced that it will present, as an oral report, Phase II clinical data for 9MW2821 – its innovative Nectin‑4‑targeted antibody‑drug conjugate…

October 19, 2026

EMA’s CHMP Backs Flexible Dosing for Regeneron’s Libtayo – Every‑Six‑Week 700 mg Regimen and Shortened Infusion Options Across All Approved PD‑1 Indications

October 19, 2026

Porton Advanced Solutions Partners with Hangzhou Aisijia Biotech on Diabetes Cell Therapy – CDMO to Provide Process Development, GMP Manufacturing and China IND Filing Support for Autologous Pancreatic Progenitor Cell Program

October 19, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.

Explore Now

Company Legal / IP